Spotlight on the January 24 Issue
暂无分享,去创建一个
C R Jack | R. Ivnik | B. Boeve | S. Przybelski | M. Senjem | D. Knopman | V. Lowe | K. Kantarci | S. Weigand | D. Knopman | R. Roberts | Y. Geda | R. C. Petersen | C. Jack | M. Senjem | G. Preboske | S D Weigand | M L Senjem | D S Knopman | R C Petersen | B F Boeve | R J Ivnik | B. Boeve | Y E Geda | K Kantarci | V Lowe | S A Przybelski | G M Preboske | R Roberts | S. Weigand | Robert A. Gross
[1] Eric M Reiman,et al. The Role of Biomarkers in Clinical Trials for Alzheimer Disease , 2006, Alzheimer disease and associated disorders.
[2] W. Jagust,et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core , 2010, Alzheimer's & Dementia.
[3] Jeffrey A. James,et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.
[4] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[5] C. Jack,et al. 11 C PiB and structural MRI provide complementary information in imaging of Alzheimer ’ s disease and amnestic mild cognitive impairment , 2008 .
[6] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[7] D. Holtzman,et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.
[8] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[9] A. Fagan,et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. , 2009, Archives of neurology.
[10] C. Rowe,et al. Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease , 2008, Neuropsychologia.
[11] A. Fagan,et al. APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.
[12] E G Tangalos,et al. Prevalence of mild cognitive impairment is higher in men , 2010, Neurology.
[13] C. Jack,et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.
[14] Gina N. LaRossa,et al. [11C]PIB in a nondemented population , 2006, Neurology.
[15] Michael Weiner,et al. Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition , 2011, Alzheimer's & Dementia.
[16] J. Ávila,et al. The in vitro formation of recombinant tau polymers: effect of phosphorylation and glycation. , 1996, Molecular and chemical neuropathology.
[17] Paul Maruff,et al. β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .
[18] Clifford R. Jack,et al. Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage , 2008, NeuroImage.
[19] E. Reiman,et al. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE ε4 allele, the major late-onset Alzheimer's susceptibility gene. , 2010, Journal of Alzheimer's disease : JAD.
[20] K. Welsh-Bohmer,et al. APOE-ε4 count predicts age when prevalence of AD increases, then declines , 1999, Neurology.
[21] A. Fagan,et al. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease , 2009, EMBO molecular medicine.
[22] Katie Hamm,et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. , 2008, The Journal of clinical investigation.
[23] Sachin Dixit,et al. APOE4 Allele Disrupts Resting State fMRI Connectivity in the Absence of Amyloid Plaques or Decreased CSF Aβ42 , 2010, The Journal of Neuroscience.
[24] D. Holtzman,et al. Apolipoprotein E in Alzheimer's disease and other neurological disorders , 2011, The Lancet Neurology.
[25] G. Alexander,et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[26] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[27] Michael Weiner,et al. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease , 2009, Annals of neurology.
[28] V. Pankratz,et al. The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics , 2008, Neuroepidemiology.
[29] G. Alexander,et al. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.
[30] D. Berlau,et al. APOE ε2 is associated with intact cognition but increased Alzheimer pathology in the oldest old , 2009, Neurology.
[31] Ge Li,et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. , 2006, Archives of neurology.
[32] W. Jagust,et al. Amyloid Imaging in Aging and Dementia: Testing the Amyloid Hypothesis In Vivo , 2009, Behavioural neurology.
[33] Michael Schemper,et al. Non-parametric partial association revisited , 1991 .
[34] R. Petersen,et al. The influence of apolipoprotein E genotype on visuospatial attention dissipates after age 80. , 2009, Neuropsychology.
[35] K. Ashe,et al. Plaque-bearing mice with reduced levels of oligomeric amyloid-β assemblies have intact memory function , 2008, Neuroscience.
[36] M. Mintun,et al. Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. , 2008, Archives of neurology.
[37] Clifford R. Jack,et al. Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition , 2011, Alzheimer's & Dementia.
[38] R. Verwer,et al. ApoE ϵ4 Genotype Is Accompanied by Lower Metabolic Activity in Nucleus Basalis of Meynert Neurons in Alzheimer Patients and Controls as Indicated by the Size of the Golgi Apparatus , 2004, Journal of neuropathology and experimental neurology.
[39] Paul Maruff,et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. , 2007, Brain : a journal of neurology.
[40] Guojun Bu,et al. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy , 2009, Nature Reviews Neuroscience.
[41] Cindee M. Madison,et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. , 2009, Brain : a journal of neurology.
[42] B W Wyse,et al. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. , 1999, Neurology.
[43] C. Rowe,et al. Imaging β-amyloid burden in aging and dementia , 2007, Neurology.